Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.21834

Article  PubMed  Google Scholar 

Bengtsson A, Andersson R, Ansari D (2020) The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep 10(1):16425. https://doi.org/10.1038/s41598-020-73525-y

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li K, Luo H, Huang L et al (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20:16. https://doi.org/10.1186/s12935-019-1091-8

Article  PubMed  PubMed Central  Google Scholar 

Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013. https://doi.org/10.1001/jamaoncol.2018.0013

Article  PubMed  PubMed Central  Google Scholar 

André T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383(23):2207–2218. https://doi.org/10.1056/NEJMoa2017699

Article  PubMed  Google Scholar 

Puliga E, Corso S, Pietrantonio F et al (2021) Microsatellite instability in Gastric cancer: between lights and shadows. Cancer Treat Rev 95:102175. https://doi.org/10.1016/j.ctrv.2021.102175

Article  PubMed  Google Scholar 

Zugasti I, Espinosa-Aroca L, Fidyt K et al (2025) Car-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther 10(1):210. https://doi.org/10.1038/s41392-025-02269-w

Article  PubMed  PubMed Central  Google Scholar 

Chen T, Wang M, Chen Y et al (2024) Current challenges and therapeutic advances of Car-T cell therapy for solid tumors. Cancer Cell Int 24(1):133. https://doi.org/10.1186/s12935-024-03315-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chohan KL, Siegler EL, Kenderian SS (2023) Car-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep 18(2):9–18. https://doi.org/10.1007/s11899-023-00687-7

Article  PubMed  PubMed Central  Google Scholar 

Huntington ND, Cursons J, Rautela J (2020) The cancer-natural killer cell immunity cycle. Nat Rev Cancer 20(8):437–454. https://doi.org/10.1038/s41568-020-0272-z

Article  PubMed  CAS  Google Scholar 

Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. https://doi.org/10.1126/science.1068440

Article  PubMed  CAS  Google Scholar 

Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051–3057. https://doi.org/10.1182/blood-2004-07-2974

Article  PubMed  CAS  Google Scholar 

Rubnitz JE, Inaba H, Ribeiro RC et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28(6):955–959. https://doi.org/10.1200/JCO.2009.24.4590

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li B, Zhu X, Ge J et al (2025) Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8(+) T cell activation in patients with advanced colorectal cancer. Mol Ther 33(9):4509–4528. https://doi.org/10.1016/j.ymthe.2025.05.026

Article  PubMed  CAS  Google Scholar 

Nieto Y, Banerjee P, Kaur I et al (2025) Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(6):1987–1993. https://doi.org/10.1038/s41591-025-03640-8

Article  PubMed  CAS  Google Scholar 

Marin D, Li Y, Basar R et al (2024) Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial. Nat Med 30(3):772–784. https://doi.org/10.1038/s41591-023-02785-8

Article  PubMed  PubMed Central  CAS  Google Scholar 

Romee R, Rosario M, Berrien-Elliott MM et al (2016) Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 8(357):357ra123. https://doi.org/10.1126/scitranslmed.aaf2341

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shapiro RM, Birch GC, Hu G et al (2022) Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. https://doi.org/10.1172/JCI154334

Article  PubMed  PubMed Central  Google Scholar 

Shapiro RM, Sheffer M, Booker MA et al (2025) First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer. J Hematol Oncol 18(1):17. https://doi.org/10.1186/s13045-025-01669-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Berrien-Elliott MM, Foltz JA, Russler-Germain DA et al (2022) Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci Transl Med 14(633):eabm1375. https://doi.org/10.1126/scitranslmed.abm1375

Article  PubMed  PubMed Central  CAS  Google Scholar 

El-Khoueiry A, Saavedra O, Thomas J et al (2025) First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors. Clin Cancer Res 31(7):1257–1267. https://doi.org/10.1158/1078-0432.CCR-24-1991

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pende D, Parolini S, Pessino A et al (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190(10):1505–1516. https://doi.org/10.1084/jem.190.10.1505

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sen Santara S, Lee DJ, Crespo  et al (2023) The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature 616(7956):348–356. https://doi.org/10.1038/s41586-023-05912-0

Article  PubMed  CAS  Google Scholar 

Koch J, Steinle A, Watzl C et al (2013) Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 34(4):182–191. https://doi.org/10.1016/j.it.2013.01.003

Article  PubMed  CAS  Google Scholar 

Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther 9(1):302. https://doi.org/10.1038/s41392-024-02005-w

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anderson P, Caligiuri M, O’Brien C et al (1990) Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A 87(6):2274–2278. https://doi.org/10.1073/pnas.87.6.2274

Article  PubMed  PubMed Central  CAS  Google Scholar 

Platonova S, Cherfils-Vicini J, Damotte D et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422. https://doi.org/10.1158/0008-5472.CAN-10-4179

Article